Is Edema Zone Volume Associated With Ki-67 Index in Glioblastoma Patients?
edema zone
glioblastoma
glioma
ki-67 labeling index
volumetric analysis
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
accepted:
17
04
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
Introduction Despite all the progress with genetic mapping and multimodal treatment, the prognosis of Glioblastoma multiforme (GBM) remains poor, with median overall survival (OS) of only 12 to 15 months. Several studies showed correlations between glioblastoma clinic and prognosis factors; however, it doesn`t occur with tumor radiological features. The purpose of this study is to determine possible correlations between the volumetric analysis of glioblastoma compartments and the proliferation index represented by Ki-67. Methods We performed a retrospective analysis of MRI studies of 70 patients with glioblastoma multiforme acquired up to one week before surgery. The tumor compartments were divided into enhancing zone; edema zone and tumor total zone. Each compartment was submitted to volumetric analysis using Horos Project software. A linear regression model was used to assess correlations between the ki-67 index and the volume of each compartment with a p-value of 0.05. Results The male/female ratio in our study was 1.7:1, at a mean age of 60.7 ± 14.6 years. Tumor predominant location was the temporal lobe with 25% of cases and cystic morphology was present in 17%. The median of Ki-67 was 40%. The average tumor compartment volume was 40 cm
Identifiants
pubmed: 35602791
doi: 10.7759/cureus.24246
pmc: PMC9116516
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e24246Informations de copyright
Copyright © 2022, Caramanti et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Neurosci. 2018 Aug;54:7-13
pubmed: 29801989
Cureus. 2022 Apr 18;14(4):e24246
pubmed: 35602791
Asian Pac J Cancer Prev. 2015;16(2):411-20
pubmed: 25684464
World Neurosurg. 2019 May;125:e1093-e1103
pubmed: 30790732
AJNR Am J Neuroradiol. 2000 Apr;21(4):659-65
pubmed: 10782774
Acta Radiol. 2015 Nov;56(11):1396-403
pubmed: 25338837
Front Oncol. 2020 Nov 16;10:580750
pubmed: 33282737
J Neurosurg. 2001 Aug;95(2):190-8
pubmed: 11780887
PLoS One. 2011;6(10):e25451
pubmed: 21998659
Neuro Oncol. 2019 Feb 19;21(3):370-379
pubmed: 30312433
Hematol Oncol Stem Cell Ther. 2019 Jun;12(2):82-88
pubmed: 30552865
Nature. 2016 Jun 29;535(7611):308-12
pubmed: 27362226
J Neurooncol. 2016 Feb;126(3):585-92
pubmed: 26603163
Neuro Oncol. 2017 Feb 1;19(2):270-280
pubmed: 27571887
Cancers (Basel). 2021 Feb 10;13(4):
pubmed: 33578746
Eur J Cancer Care (Engl). 2010 Jan 1;19(1):39-44
pubmed: 19912295
Neuro Oncol. 2011 Jul;13(7):783-90
pubmed: 21727214
Asia Pac J Clin Oncol. 2019 Feb;15(1):5-9
pubmed: 29336530
Asian Pac J Cancer Prev. 2014;15(12):4969-76
pubmed: 24998573
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
Clin Neurol Neurosurg. 2020 Nov;198:106126
pubmed: 32861131
J Neurooncol. 2017 Nov;135(2):391-402
pubmed: 28755324
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
JAMA Oncol. 2016 Nov 01;2(11):1460-1469
pubmed: 27310651
BMC Cancer. 2020 Jan 15;20(1):35
pubmed: 31941467